Gemvax & Kael said Monday that the Nature Reviews Urology, an international medical journal, published an article introducing the possibility of GV1001 as a treatment for benign prostatic hyperplasia (BPH).
Professor Clemens Thoma, the editor of Nature Reviews Urology, published the review, entitled "Signal of GV1001 efficacy." The publication went into detail on GV1001’s phase 2 clinical trial results previously introduced on BJU International in April.
“GV1001 is likely to become a successful treatment for benign prostatic hyperplasia,” Professor Thoma said. “If commercialized, it will greatly improve the patient’s convenience as patients can receive the injection every two weeks instead of taking the drug orally every day.”
Gemvax & Kael CEO showed confidence in the company’s progress in developing GV1001 as a new treatment for BPH.
“As an internationally renowned journal has verified the effects of GV1001’s effects on BPH, the company plans to accelerate the progress of domestic and global phase 3 clinical trials and its commercialization,” Gemvax & Kael CEO Song Hyoung-gon said.
Nature Reviews Urology is a magazine that publishes the latest findings in the field of urology and is one of the 18 journals of Nature review, a journal published by the world-renowned Nature Publishing Group since 2000.